CVS Health will soon add Eli Lilly’s GLP-1 medications to its commercial prescription drug formularies.
The move expands coverage for Lilly’s new GLP-1 pill, Foundayo, and the injectable drug Zepbound.
Millions more Americans could gain access to these treatments as a result of the policy change.
GLP-1 medications are primarily used for weight management and type 2 diabetes.
CVS’s decision signals broader insurer acceptance of these high-demand drugs.
The inclusion may reduce out-of-pocket costs for patients with commercial insurance plans.
This step reflects growing competition in the GLP-1 market among major pharmaceutical companies.
